Loading company…
Phagenesis develops a neurostimulation system to treat neurogenic dysphagia.
Phagenesis makes the Phagenyx® Neurostimulation System, which is used to treat swallowing difficulties and aims to restore neurological control over swallowing. Founded in 2007 and based in Manchester, UK, the company raised GBP 33.1 million in Series D funding in March 2024, co-led by EQT Life Sciences and Sectoral Asset Management, with British Patient Capital, Northern Gritstone, and Aphelion Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in